Inhibikase Therapeutics, Inc. highlighted an analysis of eleven unblinded participants from the 201 Trial evaluating risvodetinib (IkT-148009) in untreated Parkinson?s disease. These participants were withdrawn from the trial following the FDA?s temporary clinical hold in November, 2022 that was lifted in January, 2023. The Company also provided an update on the enrollment progress and recruitment tools being used in the ongoing 201 Trial.

In August 2023, Inhibikase presented an analysis of the primary and secondary endpoints performed on these eleven participants at the Movement Disorders Society Congress. Eight participants were on active drug (three at 50 mg, two at 100 mg and three at 200 mg) and three were given placebo. The primary endpoints were safety and tolerability and no participant experienced any clinically significant adverse events.

The Company also detailed changes in the functional assessments of motor and non-motor features using a hierarchical analysis of fifteen secondary endpoints. The study evaluated non-motor function, such as activities of daily living, using the MDS-UPDRS Part 2 score and evaluated motor function using the MDS-UPDRS Part 3 score. The sum of these scores is the top functional readout in the hierarchy.

Clinical improvement might be concluded if the End of Study score is lower by more than 3 to 4 points relative to the baseline score. At the End of Study timepoint, participants administered the 200 mg dose had a combined Part 2 and Part 3 score that was lower by an average of -8.7 points. By contrast, the combined placebo score increased by an average of +1.7 points, a -10.4 point spread between actively treated versus placebo participants.

Patients administered 50 or 100 mg experienced an average change of +1.7 and -1.3 points, respectively, for the combined score. An additional measure of non-motor features of disease utilized the Schwab & England Activities of Daily Life Scale (the S&E scale). The S&E scale was reduced for the 200 mg group by an average of -3.3 points relative to baseline, while the placebos had an average score increase of +3.3 points, a 6.6 point spread between the actively treated participants and the placebos; the 50 mg dose showed no effect for this measure while the 100 mg dose was on average -5.0 points lower relative to baseline.

The 201 Trial is a 12-week double-blinded study across three doses plus a placebo group, 1:1:1:1 randomized. The trial is planned to extend every enrolled participant into a 12-month extension study without placebo, but this extension study is not yet implemented. Enrollment is progressing, with 27 of 34 planned sites consenting, screening and enrolling participants.

37 people are either undergoing informed consent, being screened or have been enrolled in the trial, and three participants have completed the full 12-week regimen. The 201 Trial patient portal has been visited by more than 9,000 people since launch in September, 2023, with 5 or more new people becoming pre-qualified daily.